TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36915075

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 120
Study: 36915106

Group type: EXPERIMENTAL
Intervention: sEMG (diaphragm)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: sEMG (ICM)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Neuro-respiratory drive
Number of subjects: 29
Study: 36915138

Group type: EXPERIMENTAL
Intervention: Mobile video interpreting plus standard interpreter access
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Interactive web-based educational modules plus standard interpreter access
Number of subjects: 55

Group type: COMPARATOR
Intervention: Mobile video interpreting or educational modules (for providers with lower interpreter use after 9 months)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Patient comprehension (determined by comparing patient-reported to provider-documented visit diagnosis)
Number of subjects: 55
Study: 36915146

Group type: EXPERIMENTAL
Intervention: Methylene blue (MB)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 36915184

Group type: EXPERIMENTAL
Intervention: PTAH (Palforzia)
Number of subjects: 0
Study: 36915182

Group type: EXPERIMENTAL
Intervention: Epinephrine administration during CPR
Number of subjects: 147
Study: 36915199

Group type: EXPERIMENTAL
Intervention: Intranasal niclosamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal and inhaled ciclesonide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous sotrovimab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36915284

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36915287

Group type: COMPARATOR
Intervention: Standard treatment (increasing RUTF amount with increasing weight)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: OptiMA strategy (decreasing RUTF dose with increasing weight and MUAC)
Number of subjects: 491
Study: 36915288

Group type: EXPERIMENTAL
Intervention: hsTnT level >14 pg/mL
Number of subjects: 1739

Group type: COMPARATOR
Intervention: hsTnT level ≤14 pg/mL
Number of subjects: 1739
Study: 36915613

Group type: EXPERIMENTAL
Intervention: Molecular-instructed therapy recommendations
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Initiated therapies based on MTB recommendations
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 661
Study: 36915630

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) therapy
Number of subjects: 0
Study: 36916022

Group type: EXPERIMENTAL
Intervention: Go&Grow (social exergame)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (nonsocial exergame)
Number of subjects: 76
Study: 36916707

Group type: EXPERIMENTAL
Intervention: Synthetic human acyl ghrelin (0.1 µg/kg/min)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Acyl ghrelin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Acyl ghrelin antagonist D-Lys 3
Number of subjects: 31
Study: 36917033

Group type: EXPERIMENTAL
Intervention: Transperineal interstitial laser ablation (TPLA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 51
Study: 36917037

Group type: EXPERIMENTAL
Intervention: Herbal drug combination identified by knowledge graph
Number of subjects: 0
Study: 36917123

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (PTX)
Number of subjects: 159
Study: 36917127

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) with care bundle including antibiotic prophylaxis, oral antibiotic prophylaxis (OAP), mechanical bowel preparation, laparoscopy, normothermia, and a wound retractor.
Number of subjects: 37849

Group type: COMPARATOR
Intervention: Control Group (CG) without the care bundle.
Number of subjects: 37849

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) with care bundle.
Number of subjects: 37849
Study: 36917194

Group type: EXPERIMENTAL
Intervention: Morning Chronotype
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36917429

Group type: EXPERIMENTAL
Intervention: Risankizumab (180 mg or 360 mg) delivered subcutaneously via on-body injector (OBI)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Self-Injection Assessment Questionnaire (SIAQ)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Clinical remission (CD Activity Index < 150)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Usability assessment of OBI
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Injection site reactions
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Device-related adverse events
Number of subjects: 46
Study: 36917461

Group type: EXPERIMENTAL
Intervention: Accompanying dyspnoea
Number of subjects: 6045

Group type: COMPARATOR
Intervention: No accompanying dyspnoea
Number of subjects: 6045
Study: 36917484

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention with two additional individual visits for health and psychological education
Number of subjects: 123

Group type: COMPARATOR
Intervention: Regular outpatient consultations (Control Group)
Number of subjects: 123
Study: 36917566

Group type: EXPERIMENTAL
Intervention: 170J BTE waveform (SHOCK A)
Number of subjects: 49

Group type: COMPARATOR
Intervention: 150J BTE waveform (SHOCK B)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Attenuated 170J BTE waveform (SHOCK A)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Attenuated 150J BTE waveform (SHOCK B)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: SHOCK A
Number of subjects: 49

Group type: COMPARATOR
Intervention: SHOCK B
Number of subjects: 49
Study: 36917597

Group type: EXPERIMENTAL
Intervention: Adverse events during cMDA
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Positive attitude towards deworming and perceived ability to participate in cMDA
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Caste (SC/ST)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Occupation
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Caste and family type
Number of subjects: 74
Study: 36917594

Group type: EXPERIMENTAL
Intervention: Immune profiling panel (IPP)
Number of subjects: 1731
Study: 36917758

Group type: EXPERIMENTAL
Intervention: Low-dose tamoxifen 5 mg once daily for 3 years
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 36918123

Group type: EXPERIMENTAL
Intervention: Arthrocentesis combined with occlusal stabilization splint
Number of subjects: 40
Study: 36918157

Group type: EXPERIMENTAL
Intervention: Operating room temperature of 24°C (75°F)
Number of subjects: 5217

Group type: COMPARATOR
Intervention: Standard care operating room temperature of 20°C (67°F)
Number of subjects: 5217
Study: 36918215

Group type: EXPERIMENTAL
Intervention: Podiatry ankle duplex scan (PAD-scan) monophasic or biphasic with adverse features
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Toe brachial pressure index of ≤0.2
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Transcutaneous pressure of oxygen of ≤20 mm Hg
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Triphasic waveforms on PAD-scan
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Biphasic waveforms with non-adverse features on PAD-scan
Number of subjects: 123
Study: 36918228

Group type: EXPERIMENTAL
Intervention: Conventional treatment for FM
Number of subjects: 51

Group type: COMPARATOR
Intervention: FM individuals
Number of subjects: 51

Group type: COMPARATOR
Intervention: FM-PS cases
Number of subjects: 51
Study: 36918236

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose, 1000 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral ferrous sulfate (FS), ca. 200 mg every day
Number of subjects: 0
Study: 36918234

Group type: EXPERIMENTAL
Intervention: Groningen anti-inflammatory diet (GrAID)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Ileocolonic-delivered oral vitamin B
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 36918264

Group type: EXPERIMENTAL
Intervention: Error disclosure by NICU professionals
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Nighttime discovery of error
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Milder consequence of error
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Shorter interval between admission and error
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Error type and fewer beds
Number of subjects: 1019

Group type: EXPERIMENTAL
Intervention: Reasons for non-disclosure
Number of subjects: 1019
Study: 36918342

Group type: EXPERIMENTAL
Intervention: Amniotic fluid concentrations of procollagen
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Amniotic fluid concentrations of osteopontin
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Amniotic fluid concentrations of IL-19
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Amniotic fluid concentrations of IL-33
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Amniotic fluid concentrations of TNFα
Number of subjects: 166

Group type: COMPARATOR
Intervention: Amniotic fluid concentrations of IL-6
Number of subjects: 166

Group type: COMPARATOR
Intervention: Amniotic fluid concentrations of IL-20
Number of subjects: 166

Group type: COMPARATOR
Intervention: Amniotic fluid concentrations of TGFβ
Number of subjects: 166

Group type: COMPARATOR
Intervention: Amniotic fluid concentrations of IL-1β
Number of subjects: 166
Study: 36918384

Group type: EXPERIMENTAL
Intervention: Person-centred care competence (PCC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Person-centred care climate (PCQ-S)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between PCC and PCQ-S total scores
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nurses' educational levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nurses' individual characteristics (age, work experience)
Number of subjects: 0
Study: 36918388

Group type: EXPERIMENTAL
Intervention: Treatment effects on GFR slope
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Treatment effects on UACR change
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Combined treatment effects on UACR change and GFR slope
Number of subjects: 200
Study: 36918416

Group type: EXPERIMENTAL
Intervention: Combined protein-carbohydrate (PRO-CHO)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Carbohydrate-only (CHO)
Number of subjects: 25
Study: 36918464

Group type: EXPERIMENTAL
Intervention: Robotic-assisted surgery (RAPN)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Open partial nephrectomy (OPN)
Number of subjects: 395
Study: 36918550

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg QD on Day 1-5
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg QD with dorzagliatin 75 mg BID on Day 6-10
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dorzagliatin 75 mg BID alone on Day 11-15
Number of subjects: 15
Study: 36918846

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly (AOM)
Number of subjects: 409
Study: 36918892

Group type: EXPERIMENTAL
Intervention: Hydrolyzed collagen type II (HC-II)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Essence of chicken with added HC-II (EC-HC-II)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Glucosamine HCl
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 36918896

Group type: EXPERIMENTAL
Intervention: GFC-NHS-POx patch
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ORC-PLGA-NHS-POx: NU-POx patch
Number of subjects: 20

Group type: COMPARATOR
Intervention: TachoSil
Number of subjects: 20
Study: 36918924

Group type: EXPERIMENTAL
Intervention: Capnographic monitoring
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 1800
Study: 36918949

Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 79

Group type: COMPARATOR
Intervention: High-load resistance training (HL-RT) combined with AT
Number of subjects: 79

Group type: COMPARATOR
Intervention: Low-load resistance training (LL-RT) combined with AT
Number of subjects: 79

Group type: COMPARATOR
Intervention: Resistance training (RT) combined with AT
Number of subjects: 79
Study: 36918956

Group type: EXPERIMENTAL
Intervention: PICU Up! intervention (multifaceted early mobility intervention)
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: PICU Up! intervention
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1440
Study: 36919122

Group type: EXPERIMENTAL
Intervention: 4×4 high-intensity interval training (HIIT) protocol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10×1 high-intensity interval training (HIIT) protocol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison of both HIIT protocols
Number of subjects: 12
Study: 36919398

Group type: EXPERIMENTAL
Intervention: BI 730357 (oral treatment)
Number of subjects: 274
Study: 36919514

Group type: EXPERIMENTAL
Intervention: d-amphetamine (AMPH; 20 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Slot machine gambling (Slots)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Haloperidol (HAL; 3-mg) or fluphenazine (FLU; 3-mg)
Number of subjects: 60
Study: 36919608

Group type: EXPERIMENTAL
Intervention: lonafarnib therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: progerin-targeted treatment
Number of subjects: 0
Study: 36919800

Group type: EXPERIMENTAL
Intervention: Complex communication skills training program for physicians providing advanced cancer care
Number of subjects: 0
Study: 36919879

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36920122

Group type: EXPERIMENTAL
Intervention: Patients with pain (upregulated genes)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Patients without pain (downregulated genes)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Key genes of interest (MMP8, PCSK9, DEFA3)
Number of subjects: 40
Study: 36920158

Group type: EXPERIMENTAL
Intervention: Mobile health application based on Roy's Adaptation Model, used from 32nd-34th gestational weeks to sixth week postpartum
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no mobile health application)
Number of subjects: 62
Study: 36920397

Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg oral twice daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 80
Study: 36920449

Group type: EXPERIMENTAL
Intervention: Res-Up! (CAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: REMOTION (COMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 0
Study: 36920460

Group type: EXPERIMENTAL
Intervention: 5-month nonlinear aerobic exercise program with 3 weekly sessions
Number of subjects: 209

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 209
Study: 36920465

Group type: EXPERIMENTAL
Intervention: Smartphone and remote sensor data (Android smartphone, Withings Steel HR+, Body+, BPM Connect+)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Single-task regression models for FSHD Clinical Score and TUG test
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Multitask regression model for estimating both clinical assessments simultaneously
Number of subjects: 38
Study: 36920652

Group type: EXPERIMENTAL
Intervention: RRx-001 combined with reintroduced chemotherapy (carboplatin/cisplatin and etoposide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RRx-001
Number of subjects: 0
Study: 36920745

Group type: EXPERIMENTAL
Intervention: Remimazolam tosylate (high dose group, 0.08 mg/kg primary dose, 0-2.0 mg/kg/h adjustment range)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remimazolam tosylate (low dose group, 0.08 mg/kg primary dose, 0-2.0 mg/kg/h adjustment range)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remimazolam tosylate (both groups)
Number of subjects: 60
Study: 36920755

Group type: EXPERIMENTAL
Intervention: Inaxaplin
Number of subjects: 16
Study: 36920756

Group type: EXPERIMENTAL
Intervention: Closed-loop system of insulin delivery
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard care (insulin pump or multiple daily injections plus continuous glucose monitor)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 102
Study: 36920778

Group type: EXPERIMENTAL
Intervention: Lebrikizumab (250 mg, loading dose of 500 mg at baseline and week 2, administered subcutaneously every 2 weeks)
Number of subjects: 851

Group type: COMPARATOR
Intervention: Placebo (administered subcutaneously every 2 weeks)
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Number of subjects: 851
Study: 36921081

Group type: EXPERIMENTAL
Intervention: Elexacaftor/Tezacaftor/Ivacaftor
Number of subjects: 0
Study: 36921289

Group type: EXPERIMENTAL
Intervention: PCOS group (30 women)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (29 women)
Number of subjects: 59
Study: 36921494

Group type: EXPERIMENTAL
Intervention: vemurafenib plus cetuximab plus 5-FU/LV
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: capecitabine plus trastuzumab plus pertuzumab
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: cobimetinib plus atezolizumab
Number of subjects: 164

Group type: COMPARATOR
Intervention: fluoropyrimidine plus bevacizumab
Number of subjects: 164
Study: 36921506

Group type: EXPERIMENTAL
Intervention: Personalized cognitive stimulation program for 10 weeks
Number of subjects: 337
Study: 36921515

Group type: EXPERIMENTAL
Intervention: 4-criteria diagnostic model (lack of prior hallucinations, lack of movement disorders tremor excluded, no cognitive fluctuations, and ≥75 years of age at diagnosis)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 3/4 criteria diagnostic model
Number of subjects: 79
Study: 36921766

Group type: EXPERIMENTAL
Intervention: Ipilimumab plus stereotactic ablative radiotherapy (SABR)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sequential fractions (50 Gy/4f) to the lung
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Lung-targeted groups
Number of subjects: 106
Study: 36921804

Group type: EXPERIMENTAL
Intervention: Healthy U.S.-Style Dietary Pattern (HDP) with unprocessed or processed lean red meats
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy U.S.-Style Dietary Pattern (HDP) without lean red meats
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combined data from all 3 diet interventions
Number of subjects: 19
Study: 36921902

Group type: EXPERIMENTAL
Intervention: Lactation cookies (LCs) with galactagogues (56.5 g daily for 1 month)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Conventional cookies (56.5 g daily for 1 month)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Lactation cookies (LCs) with galactagogues
Number of subjects: 176

Group type: COMPARATOR
Intervention: Conventional cookies
Number of subjects: 176
Study: 36921903

Group type: EXPERIMENTAL
Intervention: Nonemulsified olive oil
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Emulsified olive oil
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nonemulsified coconut oil
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Emulsified coconut oil
Number of subjects: 16

Group type: COMPARATOR
Intervention: All fats tested
Number of subjects: 16
Study: 36921943

Group type: EXPERIMENTAL
Intervention: Long COVID group
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Short COVID group
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 360
Study: 36922042

Group type: EXPERIMENTAL
Intervention: TAVR care pathway and cusp overlap technique (COT)
Number of subjects: 400

Group type: COMPARATOR
Intervention: 4-step COT compliance
Number of subjects: 400
Study: 36922046

Group type: EXPERIMENTAL
Intervention: MitraClip NTR/XTR transcatheter edge-to-edge repair system
Number of subjects: 1041
Study: 36922052

Group type: EXPERIMENTAL
Intervention: Mechanical-Electric Thrombectomy
Number of subjects: 0
Study: 36922331

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg TID for 2 weeks
Number of subjects: 1258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1258
Study: 36922413

Group type: EXPERIMENTAL
Intervention: Graded Thera-Band strengthening exercises and scapular stabilization exercises 5 days a week for 8 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Traditional physical therapy program
Number of subjects: 70
Study: 36922497

Group type: EXPERIMENTAL
Intervention: Niraparib monotherapy (C1)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Niraparib and dostarlimab (C2)
Number of subjects: 47
Study: 36922593

Group type: EXPERIMENTAL
Intervention: Menin inhibitor revumenib
Number of subjects: 0
Study: 36922769

Group type: EXPERIMENTAL
Intervention: Adherence-enhancing interventions performed monthly for 3 consecutive months for adolescents with VL1 > 1000 copies/ml
Number of subjects: 280

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 280
Study: 36922777

Group type: EXPERIMENTAL
Intervention: 90 µg of vitamin D supplementation
Number of subjects: 2000

Group type: COMPARATOR
Intervention: 10 µg of vitamin D supplementation
Number of subjects: 2000
Study: 36922785

Group type: EXPERIMENTAL
Intervention: Cilofexor 100 mg once daily for up to 96 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilofexor 100 mg daily (open-label) after the blinded phase
Number of subjects: 0
Study: 36922805

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (41.4 Gy with 23 fractions) with concurrent chemotherapy (albumin-bound paclitaxel, 100 mg/m2) followed by tislelizumab.
Number of subjects: 0
Study: 36922813

Group type: EXPERIMENTAL
Intervention: Training program in clinical research (9-month duration)
Number of subjects: 6
Study: 36922807

Group type: EXPERIMENTAL
Intervention: Urban interventions in four contiguous neighborhoods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36922827

Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation program (aerobic exercises, resistance exercises, breathing exercises, psychological improvement strategies, nutritional supplementation)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Aerobic training-only program
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation program
Number of subjects: 100
Study: 36922864

Group type: EXPERIMENTAL
Intervention: Achondroplasia patients
Number of subjects: 186